Us Psychedelic Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 2,834.72 Million |
 Market Size (Forecast Year) |
USD 9,818.68 Million |
 CAGR |
% |
| Major Markets Players |
>美国迷幻药市场，按来源（合成、天然）、类型（共情剂、解离剂、其他）、药物（γ-羟基丁酸、氯胺酮、裸盖菇素、其他）、用途（发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍、其他）、给药途径（口服、吸入、注射）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房）划分——行业趋势和预测到 2029 年。
市场分析和规模
近年来，迷幻药市场预计在预测期内将快速增长。人们对全球心理健康问题的认识越来越高。根据世界卫生组织 (WHO) 2021 年发布的一项研究，精神疾病影响了全球 13% 的人口。根据该报告，每五年就有一人因精神健康问题而致残。人们因病情严重而寻求治疗。此外，一些团体发起了公众意识运动，以促进使用迷幻药治疗精神疾病。
Data Bridge Market Research 分析称，2021 年迷幻药市场价值为 28.3472 亿美元，预计到 2029 年将达到 98.1868 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 16.8%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
市场定义
迷幻药用于增强或改变感官知觉、认知过程、能量水平和精神体验。迷幻药有三种形式：共情剂、分离性药物和血清素药物。这些药物用于治疗重度抑郁症、难治性抑郁症、惊恐障碍、创伤后应激障碍和阿片类药物成瘾等疾病。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
来源（合成、天然）、类型（共情剂、解离剂、其他）、药物（γ-羟基丁酸、氯胺酮、裸盖菇素、其他）、用途（发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍、其他）、给药途径（口服、吸入、注射）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房） |
|
涵盖的市场参与者 |
Avadel（爱尔兰）、Celon Pharma SA（波兰）、Johnson & Johnson Private Limited（美国）、Hikma Pharmaceuticals PLC（英国）、Amneal Pharmaceuticals LLC.（美国）、NeuroRx, Inc.（美国）、Jazz Pharmaceuticals, Inc.（爱尔兰）、COMPASS（英国）、Develco Pharma Schweiz AG（瑞士）、Douglas Pharmaceuticals Limited（新西兰） |
|
市场机会 |
|
美国迷幻药市场动态
驱动程序
- 抑郁症和精神障碍患病率不断上升
非法物质的使用增多导致抑郁症和精神问题增多。由于抑郁症和精神疾病的患病率不断上升，对迷幻药的需求预计将上升，从而推动该行业的发展。
- 心理健康意识增强
由于广告、公众意识活动和其他手段，迷幻药变得更加知名。由于宣传活动，人们被鼓励选择适当的精神障碍治疗方法和专家，这增加了对迷幻药的需求。因此，提高心理健康意识很可能成为市场扩张的主要驱动力。
- 增加医疗基础设施投资
影响迷幻药市场增长率的另一个重要因素是医疗保健支出的增加，这有助于改善其基础设施。
此外，药店的分散化将扩大迷幻药市场。此外，高可支配收入和迷幻药用于治疗抑郁症的接受度增加将扩大迷幻药市场。与此同时，老年人口的增加和新型迷幻药的推出将提高市场增长率。
机会
- 增加研发活动数量
此外，市场的增长得益于研发活动的增加。这将为迷幻药市场的增长提供有利的机会。与此同时，药物审批和新产品发布的激增将进一步推动市场的增长速度。
此外，对先进技术开发的投资增加和新兴市场数量的增加将为预测期内迷幻药市场的增长进一步提供有利机会。
限制/挑战
另一方面，药物审批流程的延迟以及医生和药剂师之间沟通不畅将阻碍市场的增长速度。发展中经济体缺乏熟练的专业人员和缺乏医疗保健基础设施将对迷幻药市场构成挑战。此外，严格的监管政策和迷幻药的副作用激增将起到制约作用，并进一步阻碍 2022-2029 年预测期内市场的增长率。
本迷幻药市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关迷幻药市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
患者流行病学分析
迷幻药市场还为您提供详细的市场分析，用于患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更队列的多元统计模型，用于预测增长期的市场。
COVID-19 对美国迷幻药市场的影响
自 2019 年 12 月出现以来，COVID-19 病毒已传播至几乎所有国家，促使世界卫生组织 (WHO) 宣布其为公共卫生紧急事件。
由于 COVID-19 疫情期间对迷幻药的需求增加，市场正在增长。COVID-19 感染率在世界范围内不断上升。由于全球各国政府突然实施封锁，世界各地的人们都面临着巨大的创伤和压力。
近期发展
- 2020 年 1 月，杨森制药公司向欧洲药品管理局提交了 SPRAVATO 鼻喷雾剂的 II 类瓦里安申请。该提案要求鼻喷雾剂更广泛地用作抑郁症症状的急性短期疗法。这将有助于企业创造收入。
美国迷幻药市场范围
迷幻药市场根据来源、类型、药物、应用、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
来源
- 合成的
- 自然的
类型
- 共情因素
- 解离性药物
- 其他的
药物
- γ-羟基丁酸
- 氯胺酮
- 裸盖菇素
- 其他的
应用
- 嗜睡症
- 难治性抑郁症
- 重度抑郁症
- 鸦片成瘾
- 创伤后应激障碍
- 其他的
给药途径
- 口服
- 吸入
- 注射剂
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
竞争格局和美国迷幻药市场份额分析
迷幻药市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对迷幻药市场的关注有关。
美国迷幻药市场的一些主要参与者包括：
- Avadel（爱尔兰）
- Celon Pharma SA（波兰）
- 强生私人有限公司（美国）
- Hikma Pharmaceuticals PLC（英国）
- Amneal Pharmaceuticals LLC.（美国）
- NeuroRx, Inc.（美国）
- Jazz Pharmaceuticals, Inc.（爱尔兰）
- COMPASS（英国）
- Develco Pharma Schweiz AG（瑞士）
- 道格拉斯制药有限公司 (新西兰)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.S. PSYCHEDELIC DRUGS MARKET
1.4 LIMITATION
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 GEOGRAPHICAL SCOPE
2.2 YEARS CONSIDERED FOR THE STUDY
2.3 CURRENCY AND PRICING
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 PRODUCTS LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 VENDOR SHARE ANALYSIS
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRACTICING PSYCHIATRISTS
4.2 PIPELINE PRODUCTS
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS
6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS
6.2.2 HIGH COST OF PSYCHEDELIC DRUG
6.3 OPPORTUNITIES
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY
6.4 CHALLENGE
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS
7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE
7.1 OVERVIEW
7.2 SYNTHETIC
7.3 NATURAL
8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DISSOCIATIVE
8.3 EMPATHOGENS
8.4 SEROTONERGIC (CLASSICAL PSYCHEDELIC DRUGS)
9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 NARCOLEPSY
9.3 TREATMENT- RESISTANT DEPRESSION (TRD)
9.4 POST-TRAUMATIC STRESS DISORDER (PTSD)
9.5 MAJOR DEPRESSIVE DISORDER
9.6 OTHERS
10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INTRANASAL
10.4 PARENTERAL
10.5 OTHERS
11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS
11.1 OVERVIEW
11.2 GAMMA-HYDROXYBUTYRIC ACID (GHB)
11.3 KETAMINE
11.4 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)
11.5 PSILOCYBIN
12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.3 SPECIALTY CLINICS
12.4 RESEARCH ORGANISATION
12.5 OTHERS
13 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITAL PHARMACY
13.3 COMPOUNDING PHARMACY
13.4 OTHERS
14 U.S. PSYCHEDELIC DRUGS MARKET, COMPANY LANDSCAPE
15 COMPANY PROFILE
15.1 JAZZ PHARMACEUTICALS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 PIPELINE PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 JOHNSON & JOHNSON SERVICES, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
16 POTENTIAL PLAYERS PROFILE
16.1 AVADEL PHARMACEUTICALS, PLC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PIPELINE PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 AMNEAL PHARMACEUTICALS LLC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PIPELINE PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 CELON PHARMA SA
16.3.1 COMPANY SNAPSHOT
16.3.2 PIPELINE PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 COMPASS
16.4.1 COMPANY SNAPSHOT
16.4.2 PIPELINE PORTFOLIO
16.4.3 RECENT DEVELOPMENTS
16.5 DEVELCO PHARMA SCHWEIZ AG
16.5.1 COMPANY SNAPSHOT
16.5.2 PIPELINE PORTFOLIO
16.5.3 RECENT DEVELOPMENT
16.6 DOUGHLAS PHARMACEUTICALS LIMITED
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 HIKMA PHARMACEUTICALS PLC
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 NEURORX, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 USONAINSTITUTE.ORG
16.9.1 INSTITUTE SNAPSHOT
16.9.2 PIPELINE PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORT
表格列表
TABLE 1 MENTAL ILLNESS IN U.S. ADULTS IN 2018
TABLE 2 MENTAL DISORDERS IN THE U.S. ADULTS IN 2018
TABLE 3 MENTAL DISORDERS CAUSED BY USAGE OF SUBSTANCE DISORDERS IN WORLD IN 2017
TABLE 4 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS
TABLE 5 COST OF PSYCHEDELIC DRUGS
TABLE 6 PSYCHEDELIC DRUGS R&D ACTIVITIES
TABLE 7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)
TABLE 8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)
TABLE 12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 13 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (VOLUME IN 100ML)
TABLE 14 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
图片列表
FIGURE 1 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 2 U.S. PSYCHEDELIC DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 U.S. PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS
FIGURE 4 U.S. PSYCHEDELIC DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. PSYCHEDELIC DRUGS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 8 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 9 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION AND INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS ARE DRIVING THE U.S. PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 10 SYNTHETIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PSYCHEDELIC DRUGS MARKET IN 2020 & 2027
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF U.S. PSYCHEDELIC DRUGS MARKET
FIGURE 12 MENTAL ILLNESS AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP
FIGURE 13 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP:
FIGURE 14 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS IN 2018, BY GENDER :
FIGURE 15 PREVALENCE OF DEPRESSIVE DISORDERS IN 2017
FIGURE 16 PREVALENCE OF ANXIETY DISORDERS IN 2017
FIGURE 17 PREVALENCE OF BIPOLAR DISORDER IN 2017
FIGURE 18 THE RIPPLE EFFECT OF MENTAL ILLNESS
FIGURE 19 MENTAL AND SUBSTANCE USE DISORDERS GLOBALLY IN 2017
FIGURE 20 PREVALENCE OF MENTAL HEALTH DISORDERS BY DISORDER TYPE IN WORLD IN 2017
FIGURE 21 MAGIC MUSHROOMS PRICES FOR RESEARCHERS IN THE U.S.
FIGURE 22 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019
FIGURE 23 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2019-2027 (USD MILLION)
FIGURE 24 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2020-2027)
FIGURE 25 U.S. PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 26 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019
FIGURE 27 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 28 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 29 U.S. PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019
FIGURE 31 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 32 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 33 U.S. PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 35 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 36 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 37 U.S. PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2019
FIGURE 39 U.S. PSYCHEDELIC DRUGS MARKET : BY DRUGS, 2019-2027 (USD MILLION)
FIGURE 40 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2020-2027)
FIGURE 41 U.S. PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 42 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, 2019
FIGURE 43 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2019-2027 (USD MILLION)
FIGURE 44 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2020-2027)
FIGURE 45 U.S. PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 47 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 48 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 49 U.S. PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 U.S. PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2019 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
